Introduction {#S0001}
============

Pregnancy is characterized by dramatic and reversible changes in cardiovascular hemodynamic to meet the increased metabolic demands of the mother and the fetus. Early changes are due, in part, to the metabolic demands brought on by the fetus, placenta and, to the increasing levels of pregnancy hormones, particularly those of progesterone and estrogen. Later changes, starting in mid-pregnancy, are anatomical in nature and are caused by mechanical pressure from the expanding uterus ([@CIT0001]--[@CIT0005]). Heart rate increases by 10% t o 20%, and stroke volume is significantly increased as early as the eighth week of pregnancy. A 30% to 60% increase in cardiac output begins to appear early in the first trimester ([@CIT0006]). Blood volume increases by 30% to 40%, so that it is 1200 to 1600 mL greater than it is in the non-pregnant state ([@CIT0007]).

This increase begins as early as 6 weeks of gestation and plateaus by the third trimester. This dramatic change seems to be driven by increase in preload and stroke volume early in pregnancy and is maintained by an increase in heart rate late in pregnancy. Particularly in the last trimester, body position can significantly affect these variables. When the patient is in the supine position, the gravid uterus compresses the inferior vena cava, decreasing systemic venous return and preload and causing an acute reduction in cardiac output of up to 25%. Use of the left lateral decubitus position can prevent this and allows reliable and reproducible hemodynamic measurements ([@CIT0001], [@CIT0005]). The compliance of the arterial and venous systems increases in parallel with the expanding blood volume, suggesting that, acting as capacitor, this compliance is one of the body\'s adaptive mechanisms to accommodate the increase in volume ([@CIT0007], [@CIT0008]).

Increased heart rate is one of the physiological adaptations, which can be exaggerated, in some pregnant women. These palpitations can be severe enough to affect the daily activity of pregnant women. Despite the availability of treatment for symptomatic palpitation, many pregnant women are denied treatment. Up to this date, data evaluating treatment of symptomatic benign palpitation without an underlying arrhythmia are spares.

Aim of this study is to determine the number of women with benign symptomatic palpitations who receive treatment.

Methods {#S0002}
=======

We did a retrospective chart review of all pregnant patients who were referred to the obstetric-medicine clinic for evaluation of palpitation from January 2009 to December 2009 in one major maternity hospital in Kuwait. The patients were either referred from the obstetric clinics or from their family physicians at the polyclinics. We defined "benign palpitation" as sinus tachycardia without any evidence of structural heart disease or systemic causes. Data collected included: age of patient, gestational age (GA) at referral and also at delivery, symptoms at presentation, past medical history, heart rate (HR) recorded in initial visit, electrocardiogram (ECG), thyroid stimulating hormone (TSH), treatment given and Apgar score. Treatment options consisted of propranolol, digoxin, verapamil or combination of them. Digoxin was used in those patients who had systolic blood pressure \<100 mmHg at presentation. Response to treatment defined as subjective relief of palpitation with documented HR in antenatal visits was obtained from the charts of those patients who were started on treatment.

Results {#S0003}
=======

There were a total of 822 women referred to our obstetric-medicine clinic for various reasons from January 2009 to December 2009. Of the 822 patients, 27 women were referred for evaluation of palpitation. The average age was 32 yr (range 22- 45yr). Two patients were referred at first trimester (GA 10 and 11), 9 were referred at late 3^rd^ trimester (GA 35-38) and the other 18 patients were in their 2^nd^ and early 3^rd^ trimester at referral. The major complaints of all 27 women were palpitation, associated with chest tightness, nausea and presyncope. Twenty two women were previously healthy, 2 had preexisting hypertension, 1 with bronchial asthma, 1 had hypothyroidism and 1 had preexisting mitral valve prolapse. Except for 3 patients, all others had ECG done and available in the charts, which was normal apart from sinus tachycardia with HR ranging from 76 beats/min to 132 beats/min. All women had normal TSH values. Echocardiogram, which was done for all women, showed normal heart structures except for 2 patients who had mitral valve prolapse (MVP). Only seven women (25.9%) of the 27 were given treatment ([Fig. 1](#F0001){ref-type="fig"}). Three women (11.1%) were started on propranolol, two women (7.4%) received digoxin, one woman (3.7%) received verapamil and one (3.7%) received both propranolol and digoxin. One woman with MVP was not given any treatment while the other one was given digoxin because of borderline low blood pressure. All seven women reported symptomatic relief with treatment given during antenatal follow up ([Table 1](#T0001){ref-type="table"}). Nine (33.3%) of the 27 women delivered in private hospitals and therefore their postpartum data were not available in the charts. Eighteen (66.6%) women had normal deliveries with healthy babies and Apgar score at 1 minute was 6-9 and Apgar score at 5 minute was 8-9. The mother of the one baby with the lowest Apgar score of 6 at 1 minute and 8 at 5 minute was not on any treatment.

![Number of patients received treatment](MJIRI-27-31-g001){#F0001}

###### 

Patients and treatment given.

  Patient   Treatment              GA at 1^st^ visit   BP at 1^st^ visit   HR at 1^st^ visit   HR at f/u
  --------- ---------------------- ------------------- ------------------- ------------------- -----------
  1         Propranolol            15+5                120/80              132                 88
  2         Digoxin                33                  100/70              108                 104
  3         Propranolol            35                  110/80              115                 92
  4         Propranolol            33                  110/70              106                 84
  5         Digoxin                18+4                90/60               112                 84
  6         Propranolol +digoxin   28+5                120/70              116                 100
  7         Verapamil              32                  110/70              104                 80

Discussion {#S0004}
==========

Data evaluating the use of medications to control symptomatic benign palpitation in pregnant women are limited. Increased heart rate is a normal physiological adaptation occurring in pregnancy. Many pregnant women would be able to tolerate it. However, some of them would have severe tachycardia requiring medical attention and intervention.

In our study, we found that only about 25% of pregnant women with symptomatic tachycardia or palpitation receive treatment, despite the available evidence of the safety of drugs being used ([@CIT0009], [@CIT0010]). Drugs commonly used are rate control medications, which include Beta-blockers, calcium channel blockers and other antiarrhythmic agents like digoxin. Propranolol, one of the commonest Beta-blockers, which is used during pregnancy for maternal and fetal indications, has been shown not to be teratogenic. Verapamil, which is used as an antiarrhythmic agent, has also been shown to have a very low risk or nonexistent risk when used in any portion of pregnancy. Digoxin has no teratogenic effect and pregnancy recommendations show compatibility ([@CIT0011]).

In our study, all seven women who were given treatment reported resolution of their symptoms, ability to perform their activities of daily living and all delivered healthy babies. The one baby with the lowest Apgar score was not exposed to any medication.

Conclusion {#S0005}
==========

Palpitation in pregnancy is a common complaint in pregnancy. However, only a small number of patients receive treatment despite the safety of drugs that are used to control symptomatic tachycardia. The number of patients in our study is small and therefore, further larger studies are needed to evaluate the management of symptomatic benign palpitation in pregnancy.
